MTARC1 Inactivation Remodels Lipid Droplets to Protect Against Metabolic Fatty Liver Disease.

Summary

Global and liver-specific Mtarc1 knockout reduced diet-induced steatosis, injury, inflammation, and fibrosis. Mechanistically, MTARC1 deficiency post-transcriptionally upregulated CEPT1 and PEMT, remodeling lipid droplet phospholipids to shrink droplets and enhance lipophagy/lipolysis-dependent triglyceride degradation. Silencing CEPT1/PEMT reversed protection, highlighting an MTARC1–GPL biosynthesis–LD degradation axis.

Key Findings

• Global and liver-specific Mtarc1 knockout mice were protected from diet-induced steatosis, injury, inflammation, and fibrosis.
• Protection required triglyceride degradation via lipophagy and lipolysis.
• MTARC1 deficiency post-transcriptionally upregulated CEPT1 and PEMT, altering lipid droplet phospholipid composition to reduce droplet size and increase degradation.
• Knockdown of CEPT1 and PEMT reversed hepatoprotection, defining an MTARC1–GPL biosynthesis–LD degradation axis.

Clinical Implications

MTARC1 inhibition may represent a therapeutic strategy for MASLD by enhancing lipid droplet turnover via phospholipid remodeling; translational studies and pharmacologic inhibitors should be pursued.

Limitations

• Preclinical mouse and cell models; human translation and safety of MTARC1 inhibition remain untested
• Potential off-target or compensatory effects of chronic MTARC1 inhibition are unknown

Future Directions

Develop selective MTARC1 inhibitors; test efficacy/safety in NASH/MASLD models and human systems; identify biomarkers of target engagement and lipid droplet remodeling.